Advertisement Sanofi-Aventis' Taxotere shows lung cancer benefits - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sanofi-Aventis’ Taxotere shows lung cancer benefits

A meta-analysis performed on seven clinical trials in patients with advanced non-small cell lung cancer has revealed that patients receiving Sanofi-Aventis' Taxotere injection demonstrated overall survival and less febrile neutropenia than those treated with vinca-alkaloid regimens.

Petition requested FDA to require all in vitro diagnostic tests intended for use in drug or biologic therapeutic decision-making to be held to the same scientific and regulatory standards, regardless of whether they are developed and sold by device manufacturers as test kits or by laboratory-based companies for in-house testing.

Genentech is a biotechnology company that discovers, develops, manufactures and commercializes pharmaceutical products to treat patients with unmet medical needs.